U
LXRX icon

UBS’s Lexicon Pharmaceuticals LXRX Stock Holding History

UBS’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$65K Sell
6,645
-595
-8% -$6.35K ﹤0.01% 6508
2014
Q2 		$82K Sell
7,240
-310
-4% -$3.33K ﹤0.01% 6192
2014
Q1 		$92K Sell
7,550
-4,053
-35% -$51.8K ﹤0.01% 6092
2013
Q4 		$146K Buy
11,603
+4,984
+75% +$79.3K ﹤0.01% 5629
2013
Q3 		$110K Buy
6,619
+3,805
+135% +$63.8K ﹤0.01% 5902
2013
Q2 		$43K Buy
+2,814
New +$42.8K ﹤0.01% 6924

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS's LXRX Position: Q3 2014 in Review

UBS reduced its Lexicon Pharmaceuticals (LXRX) stake by 8.2% in Q3 2014, selling an estimated $6.35K and leaving 6,645 shares worth $65K. The position accounts for ﹤0.01% of the portfolio, ranked #6508.

UBS first reported a position in LXRX in Q2 2013 and has held it in 6 quarters since. The position peaked at $146K in Q4 2013. 104 funds tracked by Wall St. Rank hold LXRX as of Q3 2014.

  • UBS held 6,645 shares of Lexicon Pharmaceuticals worth $65K as of Q3 2014.
  • UBS sold 595 Lexicon Pharmaceuticals shares in Q3 2014, an estimated $6.35K.
  • Lexicon Pharmaceuticals made up ﹤0.01% of UBS's portfolio in Q3 2014, its #6508 holding.
  • UBS first reported a position in Lexicon Pharmaceuticals in Q2 2013 and has held it in 6 quarters since.
  • UBS's Lexicon Pharmaceuticals position peaked at $146K in Q4 2013.
  • 104 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.